Amy Bachrodt, SVP, Finance at Maze Therapeutics, Inc. (MAZE), sold 15,000 shares at $40.08 ($606K) on 2025-12-30, disclosed to the SEC on 2025-12-31.
Scheduled sale ($606k) by SVP, Finance under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $40.54 | 9,400 | $381K | 62.9% |
| 2 | $41.16 | 600 | $25K | 4.1% |
| 3 | $40.08 | 5,000 | $200K | 33.1% |
| Total | $40.41 avg | 15,000 | $606K | 100% |
| Filing → |
| MAZE | SELL | 2026-02-04 | $452K | — | Filing → |
| MAZE | SELL | 2026-01-26 | $455K | — | Filing → |
| MAZE | SELL | 2026-01-06 | $392K | — | Filing → |